Novavax reported on March 11 that its COVID-19 vaccine is 96% efficacious in reducing mild, moderate or severe disease. The Maryland-based company joins the handful of manufacturers that have reported encouraging data on a COVID-19 vaccine; three, Pfizer-BioNTech, Moderna and Johnson & Johnson’s Janssen Pharmaceuticals, have already received emergency use authorization for their shots from the U.S. Food and Drug Administration.
{iframe}https://time.com/5946225/novavax-covid-19-phase-3-results/?utm_medium=email&utm_source=sfmc&utm_campaign=newsletter+brief+default+ac&utm_content=+++20210312+++body&et_rid=31820950{/iframe}